ArticleThe Prostate2011
PC3 is a cell line characteristic of prostatic small cell carcinoma.
Article in The Prostate, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 287 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
287 citing papers in PubMed, 482 citations in OpenAlex.
- Article
- A bioactive pigment from violet-hued bacteria: a dual approach against prostate cancer and bacterial infections.Antonie van Leeuwenhoek · 2026Article
- Andrographolide-Loaded Gold Carbon Quantum Dots and Their Doped Derivatives for Enhanced Hydrophilicity in a Drug Delivery System.Pharmaceutics · 2026Article
- Suppression of mitochondrial energy production by a photosynthetic bacterial cupredoxin peptide inhibits tumor growth.Signal transduction and targeted therapy · 2026Article
- Article
- Article
- A Mechanistic Digital Twin of uPAR-Driven Prostate Cancer Invasion Integrating ODE Signalling and Agent-Based Modelling.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- Identification of new fucosyltransferase-8 inhibitors: An integrated biochemical, biophysical, and computational approach.PloS one · 2026Article
- Primary Cilium Forces Neuroendocrine Shift in Prostate Cancer through YAP1 Repression and Reduced Mitochondrial Activity.Theranostics · 2026Article
- Phillyrin Modulates AMPK-Associated Cellular Responses and Migration in PC3 Prostate Cancer Cells.Journal of toxicology · 2026Article
- Neuroendocrine prostate cancer (NEPC)-associatedCancer pathogenesis and therapy · 2026Article
- CDC7 is a targetable regulator of advanced prostate cancer.Scientific reports · 2025Article
- Lipoxygenase Inhibitory Activity and Prostate Cancer Cytotoxicity of In Situ- and In Vitro-Cultivated Balkan EndemicPlants (Basel, Switzerland) · 2025Article
- Running session-conditioned human serum lowers prostate cancer cell spheroid formation.Journal of cancer research and clinical oncology · 2025Article
- The Role of Metallodrugs in Enhancing Neuroendocrine Neoplasm Therapies: The Promising Anticancer Potential of Ruthenium-Based Complexes.Molecules (Basel, Switzerland) · 2025Review
- Elevated NPM1 and FBL expression correlates with prostate cancer aggressiveness and progression.The Journal of pathology · 2025Article
- Article
- Fumiquinazolines F and G from the FungusInternational journal of molecular sciences · 2025Article
227 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThe majority of the prostatic cancers are adenocarcinomas characterized by glandular formation and the expression of luminal differentiation markers androgen receptor (AR) and prostate-specific antigen (PSA). Most adenocarcinomas are indolent and androgen-dependent. Hormonal therapy that inhibits AR signaling produces symptomatic relief in patients with advanced and metastatic adenocarcinomas. Prostatic small cell neuroendocrine carcinoma (SCNC) is a variant form of prostate cancer (PC). In contrast to adenocarcinoma, the tumor cells of SCNC do not form glands and are negative for AR and PSA. SCNC is extremely aggressive and does not respond to hormonal therapy. The purpose of this study was to compare the important and relevant features of two most commonly used PC cell lines, LNCaP and PC3, with prostatic adenocarcinoma and SCNC.
methodsXenograft tumors of LNCaP and PC3 were prepared and compared with human prostatic adenocarcinoma and SCNC for the expression of key signaling molecules by immunohistochemistry and Western blot analysis.
resultsLNCaP cells express AR and PSA and their growth is inhibited by androgen withdrawal, similar to human prostatic adenocarcinoma. PC3 cells do not express AR and PSA and their proliferation is independent of androgen, similar to SCNC. Adenocarcinoma cells and LNCaP cells are negative for neuroendocrine markers and stem cell-associated marker CD44 while SCNC and PC3 cells are positive. LNCaP cells have identical cytokeratin profiles to adenocarcinoma while PC3 cells have cytokeratin profiles similar to SCNC.
conclusionLNCaP cells share common features with adenocarcinoma while PC3 cells are characteristic of SCNC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.